JP2011506400A5 - - Google Patents

Download PDF

Info

Publication number
JP2011506400A5
JP2011506400A5 JP2010537456A JP2010537456A JP2011506400A5 JP 2011506400 A5 JP2011506400 A5 JP 2011506400A5 JP 2010537456 A JP2010537456 A JP 2010537456A JP 2010537456 A JP2010537456 A JP 2010537456A JP 2011506400 A5 JP2011506400 A5 JP 2011506400A5
Authority
JP
Japan
Prior art keywords
drug substance
suspension
solvent
drug
high pressure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010537456A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011506400A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2008/067364 external-priority patent/WO2009074666A1/en
Publication of JP2011506400A publication Critical patent/JP2011506400A/ja
Publication of JP2011506400A5 publication Critical patent/JP2011506400A5/ja
Pending legal-status Critical Current

Links

JP2010537456A 2007-12-13 2008-12-11 有機化合物 Pending JP2011506400A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07123165 2007-12-13
PCT/EP2008/067364 WO2009074666A1 (en) 2007-12-13 2008-12-11 Organic compounds

Publications (2)

Publication Number Publication Date
JP2011506400A JP2011506400A (ja) 2011-03-03
JP2011506400A5 true JP2011506400A5 (enExample) 2012-02-16

Family

ID=39387173

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010537456A Pending JP2011506400A (ja) 2007-12-13 2008-12-11 有機化合物

Country Status (13)

Country Link
US (1) US20100266696A1 (enExample)
EP (1) EP2229148B1 (enExample)
JP (1) JP2011506400A (enExample)
KR (1) KR20100095587A (enExample)
CN (1) CN101896165B (enExample)
AU (1) AU2008334547B2 (enExample)
BR (1) BRPI0820745A2 (enExample)
CA (1) CA2707594C (enExample)
ES (1) ES2460576T3 (enExample)
PL (1) PL2229148T3 (enExample)
PT (1) PT2229148E (enExample)
RU (1) RU2496479C2 (enExample)
WO (1) WO2009074666A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012053654A1 (en) 2010-10-18 2012-04-26 Dainippon Sumitomo Pharma Co., Ltd. Sustained-release formulation for injection
ES2612257T3 (es) * 2011-05-03 2017-05-16 Chiesi Farmaceutici S.P.A. Formulación de suspensión mejorada de dipropionato de beclometasona para administración mediante inhalación
GB201307659D0 (en) 2013-04-26 2013-06-12 Korea Coast Guard Commissioner Preparation of drug particles by micronisation
US9393202B2 (en) 2013-04-26 2016-07-19 Chiesi Farmaceutici S.P.A Particle size reduction of an antimuscarinic compound
PT107433B (pt) * 2014-01-28 2018-12-04 Hovione Farm S A Processo de redução e controlo do tamanho de partícula
SI3191081T1 (sl) 2014-09-09 2020-07-31 Vectura Limited Formulacija, ki vsebuje glikopirolat, postopek in naprava
CN106749008A (zh) * 2015-11-23 2017-05-31 北京九和药业有限公司 一种马来酸茚达特罗的微粉化方法及其应用
PT109030B (pt) 2015-12-15 2019-09-25 Hovione Farmaciência, S.A. Preparação de partículas inaláveis de zafirlucaste
US9925168B2 (en) * 2016-01-22 2018-03-27 Chiesi Farmaceutici S.P.A. Preparation of micronized particles of an antimuscarinic compound by hydrodynamic cavitation
WO2018019803A1 (en) 2016-07-29 2018-02-01 Laboratorios Lesvi, S.L. Particle size stabilization process
CN112137957B (zh) * 2019-06-26 2022-07-29 长风药业股份有限公司 一种药用吸入气雾剂及其制备方法
WO2021216577A1 (en) * 2020-04-20 2021-10-28 Board Of Regents, The University Of Texas System Lipid nanoparticle (lnp) delivery systems and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4440337A1 (de) 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
IT1303692B1 (it) * 1998-11-03 2001-02-23 Chiesi Farma Spa Procedimento per la preparazione di sospensioni di particelle difarmaci da somministrare per inalazione.
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
GB0016040D0 (en) * 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
US8048451B2 (en) * 2000-11-30 2011-11-01 Vectura Limited Pharmaceutical compositions for inhalation
ITMI20020681A1 (it) * 2002-03-29 2003-09-29 Acs Dobfar Spa Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina
ITMI20022674A1 (it) * 2002-12-18 2004-06-19 Chiesi Farma Spa Procedimento per la preparazione di formulazioni sterili a base di principi attivi farmaceutici cristallini micronizzati da somministrare come sospensioni acquose per inalazione.
CA2559915C (en) * 2004-03-23 2013-07-02 Novartis Ag Micronization of pharmaceutically active agents
GB0409703D0 (en) * 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
EP1834624A4 (en) * 2005-01-07 2011-05-04 Eisai R&D Man Co Ltd MEDICAL COMPOSITION AND MANUFACTURING METHOD THEREFOR
WO2006105401A2 (en) * 2005-03-30 2006-10-05 Schering Corporation Medicaments and methods combining an anticholinergic, a corticosteroid, and a long acting beta agonist
WO2007024183A1 (en) * 2005-08-26 2007-03-01 Astrazeneca Ab A combination of compounds, which can be used in the treatment of respiratory diseases, especially chronic obstructive pulmonary disease (copd) and asthma
US8530463B2 (en) * 2007-05-07 2013-09-10 Hale Biopharma Ventures Llc Multimodal particulate formulations

Similar Documents

Publication Publication Date Title
JP2011506400A5 (enExample)
Salústio et al. The influence of the preparation methods on the inclusion of model drugs in a β-cyclodextrin cavity
Hao et al. Studies on the preparation, characterization and pharmacokinetics of Amoitone B nanocrystals
CN102228430B (zh) 水飞蓟宾磷脂复合物的纳米混悬剂及其制备方法
WO2014161131A1 (en) PREPARING AMORPHOUS MELOXICAM-β-CYCLODEXTRIN INCLUSION COMPLEX VIA SPRAY DRYING PROCESS
Xie et al. Novel redispersible nanosuspensions stabilized by co-processed nanocrystalline cellulose–sodium carboxymethyl starch for enhancing dissolution and oral bioavailability of baicalin
US20120231093A1 (en) Method for preparing nano-scale or amorphous particle using solid fat as a solvent
JP6845915B2 (ja) 注射のためのテコビリマットの医薬組成物およびその調製方法
JP2010526848A (ja) 難溶性薬物用の医薬組成物
Ueda et al. Equilibrium state at supersaturated drug concentration achieved by hydroxypropyl methylcellulose acetate succinate: Molecular characterization using 1H NMR technique
Zhang et al. Nanonization of megestrol acetate by liquid precipitation
US11318115B2 (en) Oral pharmaceutical composition of Tecovirimat and preparation method thereof
Pas et al. Preparation of amorphous solid dispersions by cryomilling: chemical and physical concerns related to active pharmaceutical ingredients and carriers
Kuang et al. Large-scale preparation of amorphous cefixime nanoparticles by antisolvent precipitation in a high-gravity rotating packed bed
Deshpande et al. Supercritical fluid technology: concepts and pharmaceutical applications
CN102871950B (zh) 一种熊果酸固体分散体及其制备方法
JP2023040147A (ja) インジルビン及びその誘導体を含有する新規の医薬製剤並びにその製造方法及び使用方法
Sobh et al. Formulation and in vitro characterization of anticancer drugs encapsulated chitosan/multi-walled carbon nanotube nanocomposites
Tierney et al. Carrier particle design for stabilization and isolation of drug nanoparticles
Ajinkya et al. Scaffold based drug delivery system: A special emphasis on nanosponges
Mehta et al. Improving solubility of BCS class II drugs using solid dispersion
Makarem et al. Electro-organic synthesis of nanosized particles of 2-amino-pyranes
Nep et al. Evaluation of grewia polysaccharide gum as a suspending agent
Liu et al. Preparation nanocrystals of poorly soluble plant compounds using an ultra-small-scale approach
CN105688223B (zh) 一种小粒径微晶纤维素丸芯的制备工艺